Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions
ASND Stock Forecast
Ascendis Pharma stock forecast is as follows: an average price target of $190.21 (represents a 51.24% upside from ASND’s last price of $125.77) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
ASND Price Target
The average price target for Ascendis Pharma (ASND) is $190.21 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $289.00 to $136.00. This represents a potential 51.24% upside from ASND's last price of $125.77.
ASND Analyst Ratings
According to 11 Wall Street analysts, Ascendis Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ASND stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ascendis Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Tazeen Ahmad | Bank of America Securities | $191.00 | $151.26 | 26.27% | 51.86% |
| Sep 17, 2024 | Gavin Clark-Gartner | Evercore ISI | $205.00 | $144.97 | 41.41% | 63.00% |
| Sep 17, 2024 | Leland Gershell | Oppenheimer | $190.00 | $143.90 | 32.04% | 51.07% |
| Sep 17, 2024 | David Lebowitz | Citigroup | $207.00 | $139.57 | 48.31% | 64.59% |
| Sep 17, 2024 | Derek Archila | Wells Fargo | $289.00 | $139.57 | 107.06% | 129.78% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $175.00 | $142.26 | 23.01% | 39.14% |
| Sep 16, 2024 | Paul Choi | Goldman Sachs | $200.00 | $142.26 | 40.59% | 59.02% |
| Sep 13, 2024 | David Lebowitz | Citigroup | $178.00 | $118.00 | 50.85% | 41.53% |
| Sep 05, 2024 | Leland Gershell | Oppenheimer | $180.00 | $122.40 | 47.06% | 43.12% |
| Aug 13, 2024 | Kelly Shi | Jefferies | $196.00 | $128.48 | 52.55% | 55.84% |
The latest Ascendis Pharma stock forecast, released on Sep 23, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $191.00, which represents a 26.27% increase from the stock price at the time of the forecast ($151.26), and a 51.86% increase from ASND last price ($125.77).
Ascendis Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 10 | 13 |
| Avg Price Target | - | $201.10 | $195.54 |
| Last Closing Price | $125.77 | $125.77 | $125.77 |
| Upside/Downside | -100.00% | 59.90% | 55.47% |
In the current month, the average price target of Ascendis Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ascendis Pharma's last price of $125.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 17, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 17, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Sep 16, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 16, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 10, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 04, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 13, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 12, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Ascendis Pharma's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave ASND a "Buy" rating, the same as its previous rate.
Ascendis Pharma Financial Forecast
Ascendis Pharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $33.59M | $22.90M | $15.29M | $6.16M | $6.83M | $4.90M | $1.11M | $1.02M | $746.00K | $535.00K | $2.76M | $1.44M | $2.23M | $2.51M | $2.24M | $3.21M | $5.41M | $28.00K | $372.00K |
| Avg Forecast | $159.14M | $132.31M | $107.84M | $94.49M | $86.16M | $68.20M | $82.80M | $79.81M | $93.73M | $49.05M | $37.24M | $21.50M | $19.15M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M | $938.20K | $4.39M | $20.80K | $290.16K |
| High Forecast | $159.14M | $132.31M | $107.84M | $94.49M | $86.16M | $94.12M | $85.38M | $82.73M | $160.04M | $50.38M | $37.24M | $21.50M | $19.15M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M | $938.20K | $4.39M | $24.95K | $348.19K |
| Low Forecast | $159.14M | $132.31M | $107.84M | $94.49M | $86.16M | $55.91M | $80.23M | $76.89M | $61.23M | $47.72M | $37.24M | $21.50M | $19.15M | $8.81M | $5.60M | $4.55M | $2.71M | $1.14M | $746.43K | $1.64M | $1.69M | $1.39M | $2.18M | $2.12M | $1.90M | $1.40M | $938.20K | $4.39M | $16.64K | $232.13K |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.56% | 1.20% | 1.73% | 1.10% | 1.50% | 1.81% | 0.98% | 1.37% | 0.45% | 0.32% | 1.98% | 0.66% | 1.05% | 1.32% | 1.60% | 3.42% | 1.23% | 1.35% | 1.28% |
Ascendis Pharma's average Quarter revenue forecast for Jun 23 based on 3 analysts is $37.24M, with a low forecast of $37.24M, and a high forecast of $37.24M. ASND's average Quarter revenue forecast represents a 10.86% increase compared to the company's last Quarter revenue of $33.59M (Mar 23).
Ascendis Pharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-95.23M | $-176.65M | $-123.36M | $-67.54M | $-115.44M | $-100.57M | $-75.68M | $-118.68M | $-58.40M | $-174.47M | $-79.52M | $-82.55M | $-60.95M | $-78.02M | $-22.89M | $-48.97M | $-52.22M | $-34.27M | $-23.26M |
| Avg Forecast | $-159.14M | $-132.31M | $-107.84M | $-94.49M | $-86.16M | $-68.20M | $-82.80M | $-79.81M | $-93.73M | $-49.05M | $-37.24M | $-21.50M | $-19.15M | $-8.81M | $-5.60M | $-93.33M | $-2.71M | $-1.14M | $-746.43K | $-65.11M | $-1.69M | $-1.39M | $-2.18M | $-57.26M | $-1.90M | $-1.40M | $-938.20K | $-35.32M | $-16.97M | $-18.14M |
| High Forecast | $-159.14M | $-132.31M | $-107.84M | $-94.49M | $-86.16M | $-55.91M | $-80.23M | $-76.89M | $-61.23M | $-47.72M | $-37.24M | $-21.50M | $-19.15M | $-8.81M | $-5.60M | $-74.66M | $-2.71M | $-1.14M | $-746.43K | $-52.09M | $-1.69M | $-1.39M | $-2.18M | $-45.81M | $-1.90M | $-1.40M | $-938.20K | $-28.26M | $-13.58M | $-14.52M |
| Low Forecast | $-159.14M | $-132.31M | $-107.84M | $-94.49M | $-86.16M | $-94.12M | $-85.38M | $-82.73M | $-160.04M | $-50.38M | $-37.24M | $-21.50M | $-19.15M | $-8.81M | $-5.60M | $-111.99M | $-2.71M | $-1.14M | $-746.43K | $-78.13M | $-1.69M | $-1.39M | $-2.18M | $-68.72M | $-1.90M | $-1.40M | $-938.20K | $-42.39M | $-20.36M | $-21.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.43% | 9.22% | 14.00% | 12.07% | 1.24% | 37.10% | 66.57% | 159.00% | 0.90% | 103.20% | 57.15% | 37.87% | 1.06% | 41.09% | 16.37% | 52.20% | 1.48% | 2.02% | 1.28% |
undefined analysts predict ASND's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ascendis Pharma's previous annual EBITDA (undefined) of $NaN.
Ascendis Pharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-110.91M | $-207.42M | $-168.96M | $-81.32M | $-125.50M | $-106.06M | $-80.35M | $-134.37M | $-62.79M | $-138.97M | $-121.74M | $-94.93M | $-63.32M | $-80.36M | $-25.11M | $-58.90M | $-53.64M | $-41.38M | $-25.14M |
| Avg Forecast | $-19.44M | $-38.18M | $-69.72M | $-77.66M | $-81.19M | $-88.23M | $-83.47M | $-85.03M | $-104.37M | $-136.40M | $-144.68M | $-151.90M | $-151.12M | $-146.33M | $-124.28M | $-101.46M | $-132.40M | $-131.89M | $-127.81M | $-70.00M | $-90.00M | $-90.16M | $-83.77M | $-59.48M | $-68.87M | $-68.44M | $-69.76M | $-36.28M | $-20.49M | $-19.61M |
| High Forecast | $-19.44M | $-38.18M | $-69.72M | $-77.66M | $-81.19M | $38.75M | $-83.47M | $-85.03M | $-28.16M | $-136.40M | $-144.68M | $-151.90M | $-151.12M | $-146.33M | $-124.28M | $-81.17M | $-132.40M | $-131.89M | $-127.81M | $-56.00M | $-90.00M | $-90.16M | $-83.77M | $-47.59M | $-68.87M | $-68.44M | $-69.76M | $-29.03M | $-16.39M | $-15.69M |
| Low Forecast | $-19.44M | $-38.18M | $-69.72M | $-77.66M | $-81.19M | $-126.38M | $-83.47M | $-85.03M | $-212.63M | $-136.40M | $-144.68M | $-151.90M | $-151.12M | $-146.33M | $-124.28M | $-121.75M | $-132.40M | $-131.89M | $-127.81M | $-84.00M | $-90.00M | $-90.16M | $-83.77M | $-71.38M | $-68.87M | $-68.44M | $-69.76M | $-43.54M | $-24.58M | $-23.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 1.37% | 1.15% | 0.65% | 1.24% | 0.80% | 0.61% | 1.05% | 0.90% | 1.54% | 1.35% | 1.13% | 1.06% | 1.17% | 0.37% | 0.84% | 1.48% | 2.02% | 1.28% |
Ascendis Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ASND's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Ascendis Pharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $66.54M | $56.55M | $60.67M | $56.58M | $47.42M | $48.30M | $39.28M | $35.34M | $37.25M | $20.43M | $17.52M | $20.80M | $17.91M | $17.08M | $10.00M | $10.96M | $10.44M | $4.66M | $3.33M |
| Avg Forecast | $1.29B | $1.07B | $874.78M | $766.50M | $698.94M | $553.26M | $671.70M | $647.41M | $760.29M | $397.90M | $302.05M | $174.44M | $155.35M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M | $7.61M | $35.61M | $168.69K | $2.35M |
| High Forecast | $1.29B | $1.07B | $874.78M | $766.50M | $698.94M | $763.47M | $692.60M | $671.11M | $1.30B | $408.71M | $302.05M | $174.44M | $155.35M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M | $7.61M | $35.61M | $202.42K | $2.82M |
| Low Forecast | $1.29B | $1.07B | $874.78M | $766.50M | $698.94M | $453.54M | $650.80M | $623.71M | $496.67M | $387.09M | $302.05M | $174.44M | $155.35M | $71.49M | $45.39M | $36.88M | $21.99M | $9.22M | $6.05M | $13.32M | $13.71M | $11.29M | $17.68M | $17.20M | $15.40M | $11.34M | $7.61M | $35.61M | $134.95K | $1.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.38% | 0.36% | 0.85% | 1.25% | 1.29% | 2.20% | 4.26% | 5.84% | 2.80% | 1.49% | 1.55% | 1.18% | 1.04% | 1.11% | 0.88% | 1.44% | 0.29% | 27.64% | 1.41% |
Ascendis Pharma's average Quarter SG&A projection for Jun 23 is $302.05M, based on 3 Wall Street analysts, with a range of $302.05M to $302.05M. The forecast indicates a 353.95% rise compared to ASND last annual SG&A of $66.54M (Mar 23).
Ascendis Pharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 3 | 6 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 13 | 7 | 7 | 9 | 8 | 6 | 10 | 6 | 14 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-1.98 | $-3.72 | $-3.03 | $-1.46 | $-2.21 | $-1.97 | $-1.47 | $-2.50 | $-1.17 | $-2.58 | $-2.31 | $-1.97 | $-1.32 | $-1.67 | $-0.53 | $-1.25 | $-1.24 | $-1.07 | $-0.78 |
| Avg Forecast | $-0.34 | $-0.67 | $-1.22 | $-1.35 | $-1.42 | $-1.54 | $-1.46 | $-1.48 | $-1.82 | $-2.38 | $-2.52 | $-2.65 | $-2.64 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 | $-1.22 | $-0.90 | $-0.38 | $-0.52 |
| High Forecast | $-0.34 | $-0.67 | $-1.22 | $-1.35 | $-1.42 | $0.68 | $-1.46 | $-1.48 | $-0.49 | $-2.38 | $-2.52 | $-2.65 | $-2.64 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 | $-1.22 | $-0.90 | $-0.31 | $-0.42 |
| Low Forecast | $-0.34 | $-0.67 | $-1.22 | $-1.35 | $-1.42 | $-2.20 | $-1.46 | $-1.48 | $-3.71 | $-2.38 | $-2.52 | $-2.65 | $-2.64 | $-2.55 | $-2.17 | $-2.06 | $-2.31 | $-2.30 | $-2.23 | $-1.81 | $-1.57 | $-1.57 | $-1.46 | $-1.33 | $-1.20 | $-1.19 | $-1.22 | $-0.90 | $-0.45 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 1.41% | 1.19% | 0.67% | 1.07% | 0.85% | 0.64% | 1.12% | 0.65% | 1.64% | 1.47% | 1.35% | 0.99% | 1.39% | 0.44% | 1.03% | 1.38% | 2.81% | 1.49% |
According to undefined Wall Street analysts, Ascendis Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ASND previous annual EPS of $NaN (undefined).
Ascendis Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| ASND | Ascendis Pharma | $125.77 | $190.21 | 51.24% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| BGNE | BeiGene | $207.25 | $255.80 | 23.43% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| UTHR | United Therapeutics | $376.80 | $358.20 | -4.94% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
ASND Forecast FAQ
Is Ascendis Pharma a good buy?
Yes, according to 11 Wall Street analysts, Ascendis Pharma (ASND) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of ASND's total ratings.
What is ASND's price target?
Ascendis Pharma (ASND) average price target is $190.21 with a range of $136 to $289, implying a 51.24% from its last price of $125.77. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ascendis Pharma stock go up soon?
According to Wall Street analysts' prediction for ASND stock, the company can go up by 51.24% (from the last price of $125.77 to the average price target of $190.21), up by 129.78% based on the highest stock price target, and up by 8.13% based on the lowest stock price target.
Can Ascendis Pharma stock reach $200?
ASND's highest twelve months analyst stock price target of $289 supports the claim that Ascendis Pharma can reach $200 in the near future.
What are Ascendis Pharma's analysts' financial forecasts?
Ascendis Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $316.98M (high $348.39M, low $299.19M), average EBITDA is $-317M (high $-299M, low $-348M), average net income is $-338M (high $-211M, low $-376M), average SG&A $2.57B (high $2.83B, low $2.43B), and average EPS is $-5.893 (high $-3.679, low $-6.558). ASND's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $493.78M (high $493.78M, low $493.78M), average EBITDA is $-494M (high $-494M, low $-494M), average net income is $-205M (high $-205M, low $-205M), average SG&A $4.01B (high $4.01B, low $4.01B), and average EPS is $-3.575 (high $-3.575, low $-3.575).
Did the ASND's actual financial results beat the analysts' financial forecasts?
Based on Ascendis Pharma's last annual report (Dec 2022), the company's revenue was $51.17M, beating the average analysts forecast of $38.11M by 34.30%. Apple's EBITDA was $-527M, beating the average prediction of $-127M by 315.59%. The company's net income was $-583M, beating the average estimation of $-523M by 11.47%. Apple's SG&A was $221.23M, missing the average forecast of $309.1M by -28.43%. Lastly, the company's EPS was $-10.4, beating the average prediction of $-9.411 by 10.51%. In terms of the last quarterly report (Mar 2023), Ascendis Pharma's revenue was $33.59M, beating the average analysts' forecast of $21.5M by 56.20%. The company's EBITDA was $-95.231M, beating the average prediction of $-21.504M by 342.85%. Ascendis Pharma's net income was $-111M, missing the average estimation of $-152M by -26.98%. The company's SG&A was $66.54M, missing the average forecast of $174.44M by -61.86%. Lastly, the company's EPS was $-1.98, missing the average prediction of $-2.649 by -25.25%